Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Discovery & Development

Discovery & Development Clinical Trials

What Women Want

| Stephanie Sutton

Women, like men, want good medicines that have been tested in clinical trials involving fair representation of both sexes.

Discovery & Development Business Practice

In Conversation with Christophe Le Ret of Umicore Precious Metals Chemistry at CPhI 2017

Here, James speaks with Christophe Le Ret from Umicore.

Discovery & Development Business Practice

In Conversation with Michel Lagarde from Patheon part of Thermo Fisher Scientific at CPhI 2017

Here, James speaks with Michel Lagarde from Thermo Fischer Scientific (Patheon).

Discovery & Development Business Practice

In Conversation with Tony van Bijleveld from Patheon part of Thermo Fisher Scientific at CPhI 2017

Here, James speaks with Tony van Bijleveld from Thermo Fischer Scientific (Patheon).

Discovery & Development Standards & Regulation

The End of “Mini-Me” Medicine

| Andrew Parker

The end of “mini me” medicine is over, says Andrew Parker, because we can do better when it comes to pediatric care.

Discovery & Development Contract Development Services

Trials of a Medicine Maker

What is the current state of pharma contract development and manufacturing?

Discovery & Development Analytical Science

Pure and Simple(r)

| Stephanie Sutton

Making cancer drugs cheaper and more effective – with a paper “coffee” filter.

Discovery & Development Contract Development Services

A Nice Outsourcing View

| Stephanie Sutton

What is the current state of pharma contract development and manufacturing?

Discovery & Development Clinical Trials

Coping With the Complex Clinical Trial Landscape…

| James Strachan

Valarie Higgins discusses how clinical trials have evolved over the years and the key lessons she has learned while building her career in the industry.

Discovery & Development Bioprocessing - Upstream & Downstream

Boosting mAb Manufacture

| David Westman

mAbs are an important growth area for the biopharma industry – so we need more effective purification technologies.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register